论文部分内容阅读
目的观察宫颈环扎术联合硫酸镁治疗早产临产的临床效果。方法选择2010年1月—2013年6月收治的20~34周早产临产住院孕妇66例,随机分为A组和B组各33例。A组采用宫颈环扎术联合硫酸镁治疗,B组给予单纯硫酸镁治疗。记录并比较两组患者分娩孕周、延长妊娠天数及32、34、37周前分娩情况,并对新生儿结局、孕产妇感染情况进行分析。计量资料采用t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果 A组平均分娩孕周、延长妊娠平均天数分别为(35.12±7.45)周、(42.56±25.72)d,B组分别为(27.79±4.33)周、(4.52±10.77)d,差异均有统计学意义(均P<0.05)。A组32、34、37周前分娩率(21.21%、36.36%、75.76%)均低于B组(60.61%、90.91%、96.97%),差异均有统计学意义(均P<0.05)。A组新生儿死亡率及窒息率分别为6.06%、21.21%,低于B组的36.36%、54.55%,差异均有统计学意义(均P<0.05)。结论宫颈环扎术联合硫酸镁治疗早产临产能增加分娩孕周,减少32、34、37周前分娩率,降低新生儿死亡率及窒息率,临床效果显著,值得进一步推广。
Objective To observe the clinical effect of cervical cerclage combined with magnesium sulfate in preterm delivery. Methods Sixty-six pregnant women were interviewed in our hospital from January 2010 to June 2013 in preterm delivery of 20 to 34 weeks. They were randomly divided into group A and group B, with 33 cases each. A group of cervical cerclage combined with magnesium sulfate treatment, B group given simple magnesium sulfate treatment. The gestational weeks of childbirth, the number of gestational days and delivery before 32, 34 and 37 weeks were recorded and compared. The neonatal outcome and maternal infection were analyzed. Measurement data using t test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results The mean number of gestational weeks and prolonged pregnancies in group A were (35.12 ± 7.45) weeks and (42.56 ± 25.72) days, respectively, and those in group B were (27.79 ± 4.33) weeks and (4.52 ± 10.77) days, respectively Significance (both P <0.05). Group A 32,34,37 weeks before delivery rate (21.21%, 36.36%, 75.76%) were lower than the B group (60.61%, 90.91%, 96.97%), the differences were statistically significant (P <0.05). Neonatal mortality and asphyxia in group A were 6.06% and 21.21%, respectively, which were lower than those in group B (36.36% and 54.55%, both P <0.05). Conclusions Cervical cerclage combined with magnesium sulfate in preterm delivery can increase gestational age of delivery, reduce delivery rate before 32,34 and 37 weeks, reduce neonatal mortality rate and asphyxia rate. The clinical effect is worthy of further promotion.